Fubotv earnings beat by $0.10, revenue topped estimates
Vinayak Doraiswamy, Chief Scientific Officer of AtriCure , Inc. (NASDAQ:ATRC), sold 2,500 shares of common stock on August 5, 2025, at a price of $36.58, for a total value of $91,450. The medical device company, with a market capitalization of $1.82 billion, has shown strong momentum with a 79.5% return over the past year and impressive revenue growth of 16.3%.
Following the transaction, Doraiswamy directly owns 71,872 shares of AtriCure. The company maintains a healthy financial position with a current ratio of 3.94, indicating strong liquidity. According to InvestingPro analysis, AtriCure’s stock is currently trading near its Fair Value, with additional insights available in the comprehensive Pro Research Report.
In other recent news, AtriCure reported impressive second-quarter 2025 financial results, surpassing analyst expectations. The company achieved a revenue increase to $136.1 million, exceeding forecasts of $130.17 million, and reported an earnings per share (EPS) of -$0.13, better than the anticipated -$0.17. This strong performance led AtriCure to raise its full-year 2025 guidance for revenue, adjusted EBITDA, and EPS. Following these results, Needham raised its price target for AtriCure to $45, maintaining a Buy rating. JMP Securities also reiterated its Market Outperform rating with a $60 price target, noting AtriCure’s quarterly sales growth of 17% year-over-year and a significant increase in adjusted EBITDA to $15.4 million. These developments reflect investor confidence in AtriCure’s strategic direction and financial management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.